Heparina Sódica B Braun

Heparina Sódica B Braun is a pharmaceutical product containing the active ingredient heparin sodium. It is supplied as an injectable solution for intravenous or subcutaneous administration, marketed in the European Union. The preparation is prescription‑only and belongs to the anticoagulant drug class, used to inhibit clot formation. It is formulated to provide rapid anticoagulant effect and is commonly used in hospital settings for prophylaxis and treatment of thromboembolic disorders.

Heparina Sódica B Braun is indicated for clinical situations where anticoagulation is required to prevent or treat abnormal clot formation.

- Prevention of venous thromboembolism in surgical or immobilized patients. - Treatment of acute deep vein thrombosis and pulmonary embolism. - Anticoagulation during cardiac surgery or extracorporeal circulation. - Management of heparin‑induced thrombocytopenia when alternative agents are not available. - Use as a bridge therapy during transition to oral anticoagulants.

Adverse reactions to Heparina Sódica B Braun vary in frequency and severity; they are categorized as common or serious.

Common: - Minor bleeding at injection site. - Small bruising or hematoma formation. - Mild nausea or vomiting. - Transient elevation of liver enzymes.

Serious: - Major hemorrhage requiring medical intervention. - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Allergic reactions such as urticaria or anaphylaxis. - Spinal or epidural hematoma after neuraxial procedures.

Before prescribing Heparina Sódica B Braun, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess baseline coagulation parameters and platelet count. - Adjust dose in patients with renal or hepatic impairment. - Avoid use in active uncontrolled bleeding or recent intracranial hemorrhage. - Use cautiously in pregnancy; benefits must outweigh risks. - Monitor for signs of heparin‑induced thrombocytopenia during therapy. - Discontinue before invasive procedures to reduce bleeding risk.

Heparina Sódica B Braun can interact with other medications, influencing anticoagulant effect or bleeding risk.

Avoid: - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants). - Combination with antiplatelet agents such as aspirin or clopidogrel. - Concomitant administration of fibrinolytic drugs.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding. - Certain antibiotics (e.g., quinolones) that can affect platelet function. - High‑dose corticosteroids that may potentiate anticoagulation.